Jump Financial LLC Acquires New Position in Stryker Co. (NYSE:SYK)

Jump Financial LLC bought a new position in shares of Stryker Co. (NYSE:SYK) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 11,676 shares of the medical technology company’s stock, valued at approximately $4,204,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Morse Asset Management Inc lifted its holdings in Stryker by 16.5% in the third quarter. Morse Asset Management Inc now owns 1,410 shares of the medical technology company’s stock valued at $509,000 after acquiring an additional 200 shares during the last quarter. World Investment Advisors LLC lifted its stake in shares of Stryker by 126.1% in the 3rd quarter. World Investment Advisors LLC now owns 8,142 shares of the medical technology company’s stock valued at $2,941,000 after purchasing an additional 4,541 shares during the last quarter. Arvest Bank Trust Division purchased a new position in shares of Stryker during the 3rd quarter worth $245,000. Wilmington Savings Fund Society FSB increased its position in shares of Stryker by 13.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 44,795 shares of the medical technology company’s stock worth $16,183,000 after purchasing an additional 5,361 shares during the last quarter. Finally, Tidal Investments LLC increased its position in shares of Stryker by 13.9% during the 3rd quarter. Tidal Investments LLC now owns 17,478 shares of the medical technology company’s stock worth $6,314,000 after purchasing an additional 2,139 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on SYK shares. The Goldman Sachs Group set a $422.00 target price on shares of Stryker in a research note on Tuesday, March 4th. Argus set a $450.00 price objective on shares of Stryker in a report on Monday, February 3rd. BTIG Research set a $403.00 target price on shares of Stryker and gave the company a “buy” rating in a report on Monday. Needham & Company LLC restated a “buy” rating and set a $442.00 price target on shares of Stryker in a research note on Friday, March 21st. Finally, Royal Bank of Canada lifted their price objective on Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research note on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $423.53.

Insider Transactions at Stryker

In related news, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares of the company’s stock, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Price Performance

Shares of SYK opened at $346.69 on Thursday. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The firm’s fifty day simple moving average is $372.75 and its 200-day simple moving average is $373.21. The firm has a market capitalization of $132.33 billion, a price-to-earnings ratio of 44.68, a PEG ratio of 2.93 and a beta of 0.93. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the business posted $3.46 earnings per share. Equities analysts forecast that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.97%. Stryker’s payout ratio is currently 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.